April 16th, 2002

Blood 2002-01-0015

Brief Report

**Rta of the human herpesvirus 8/Kaposi’s sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression**

Hongyu Deng, Julia T. Chu, Matthew B. Rettig, Otoniel Martinez-Maza, and Ren Sun*

*Department of Molecular and Medical Pharmacology, Department of Medicine (West LA VAMC), Department of Obstetrics and Gynecology, Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, AIDS Institute, Molecular Biology Institute and Dental Research Institute, University of California at Los Angeles, USA

Running title: HHV-8/KSHV Rta up-regulates hIL-6

Supported by NIH grants CA91791, CA83525, DE14153, CA57152, Jonsson Cancer Center Foundation, Stop Cancer Foundation, and Concern Foundation. H. Deng is a Lymphoma Research Foundation Fellow.

*Reprints: Department of Molecular & Medical Pharmacology, University of California at Los Angeles, Los Angeles, CA 90095-1735. Phone: (310) 794-5557. Fax: (310) 825-6267. E-mail: rsun@mednet.ucla.edu.

Word counts: 1171 in text; 128 in abstract
Human herpesvirus 8 (HHV-8)/Kaposi’s sarcoma-associated herpesvirus (KSHV) is linked to a number of malignancies that are thought to be driven by cytokines including interleukin-6 (IL-6). Rta, a transcriptional activator encoded by HHV-8/KSHV, activates the viral lytic cycle leading to expression of several viral genes that are implicated in viral pathogenesis. However, the effect of HHV-8/KSHV Rta on cellular genes has not been reported. We present evidence that the human IL-6 (hIL-6) gene is up-regulated by Rta. Rta potently activated (up to 164-fold) the hIL-6 promoter in a dose-dependent manner in a transient transfection reporter system. Rta also induced expression of the endogenous hIL-6 gene, as shown by enzyme-linked immunosorbent assays. Activation of the hIL-6 gene by HHV-8/KSHV supports the role of hIL-6 in the development of these malignancies.

Corresponding author: Ren Sun (rsun@mednet.ucla.edu)

Introduction

Human interleukin-6 (hIL-6) is a multifunctional cytokine and dysregulation of hIL-6 is implicated in the pathogenesis of several malignancies such as Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). hIL-6 serves as an autocrine growth factor for cultured AIDS-KS cells and may induce endothelial cell proliferation in KS via a paracrine pathway.1,2 Both supernatants from PEL-derived cell lines and PEL effusions contain large quantities of hIL-6.3,4 Anti-hIL-6 neutralizing antibodies delayed PEL tumor progression in SCID mice.5 Overproduction of IL-6 also reproduced some manifestations of MCD in a mouse model.6 Furthermore, anti-hIL-6 or anti-hIL-6 receptor antibodies exerted a therapeutic effect on MCD patients.7,8 Taken together, these data strongly support the involvement of hIL-6 in the pathogenesis of these malignancies.

Another common feature of KS, PEL and MCD is their association with human herpesvirus 8 (HHV-8)/Kaposi’s sarcoma-associated herpesvirus (KSHV).9-11 HHV-8/KSHV encodes a potent transcriptional activator, Rta, which is necessary and sufficient for initiating viral lytic replication.12,13 Among the lytic genes expressed are homologues of cytokines and chemokines including viral IL-6 (vIL-6) and viral macrophage inflammatory proteins.14,15 In particular, vIL-6 has been detected in tumor lesions as well as sera from KS, PEL and MCD patients, and is thought to play an important role in viral pathogenesis.16-18 In addition to pirating cellular genes, it is very likely that HHV-8/KSHV has developed strategies to enhance its replication by modulating the regulation of cellular factors. We are investigating the effect of Rta on cellular genes and report here that hIL-6 expression is up-regulated by Rta.

Methods

Plasmid construction. The 1.2 kb hIL-6 promoter region was amplified from total cellular DNA using primers F (5’-GGAAGATCTTCTTCTGCAAGACACCATCCTGA-3’) and R (5’-CGGGAATTCAGGAGGAGATGAGCCTCAGAGACAT3’); the underlined nucleotides

Deng et al.
represent Bgl II and EcoR I sites, respectively. The PCR fragment was cloned into pSEAP2-basic (Clontech) to produce phIL6-1200/SEAP.

**Reporter assays.** Transfections were performed in 12-well plates using a standard calcium phosphate method (Current Protocols in Molecular Biology) for the human embryonic kidney cell line 293T or LipofectAmine PLUS (Invitrogen) for the immortalized bone marrow stromal cell line R1T. At 48 hr post-transfection, both supernatants and cells were harvested. The supernatants were assayed for secreted alkaline phosphatase (SEAP) activities, using the Great EscAPe SEAP Chemiluminescence Detection Kit (Clontech). The cells were lysed in 1 x Passive Lysis Buffer and assayed for Renilla luciferase activities, using a Luciferase Reporter Assay System (Promega).

**Enzyme-linked immunosorbent assays (ELISA).** pcDNA3/Rta or pcDNA3 was transfected into 293T or R1T cells in 6-well plates using LipofectAmine PLUS. pcDNA3/Rta contains a 3.1-kb genomic sequence encoding Rta, whose expression is driven by the CMV immediate-early promoter/enhancer in the vector. Supernatants from transfected cells were collected at 24, 48, and 72 hr post-transfection, and assayed for hIL-6 protein levels using an hIL-6 ELISA kit (Biosource International).

**Results and Discussion**

To investigate the role Rta may play in regulating hIL-6 gene expression, we first examined whether Rta can activate the hIL-6 promoter in a reporter system. A 1200-bp promoter region upstream of the first hIL-6 exon was cloned into the pSEAP2-basic vector to produce phIL6-1200/SEAP. This reporter plasmid was co-transfected into 293T cells with either pcDNA3/Rta (a Rta expression plasmid) or vector alone. To control for transfection efficiency and other experimental variations, pRL-CMV which constitutively expresses the Renilla luciferase was included in each transfection. As shown in Figure 1A, phIL6-1200/SEAP was potently activated (164-fold) by Rta. To confirm that activation of the hIL-6 promoter was mediated by the Rta protein, we examined the dose-dependence of Rta activation. A fixed amount of the reporter plasmid phIL6-1200/SEAP was co-transfected with increasing amounts of pcDNA3/Rta into 293T cells. As the amount of pcDNA3/Rta in each transfection increased, so did the normalized SEAP activity (Figure 1B), indicating that activation of the hIL-6 promoter by Rta is specific.

These results from the reporter system indicate that Rta activates the hIL-6 promoter in the absence of chromatin structure. We next examined whether Rta also activates the endogenous hIL-6 gene. pcDNA3/Rta or pcDNA3 was transfected into 293T cells, and supernatants were harvested at different time points post-transfection. The hIL-6 protein levels in these samples were then assayed by ELISA. Consistent with the lack of endogenous hIL-6 expression in 293T cells, the hIL-6 protein levels were very low (<7.8 pg/ml, the detection limit of the kit) in pcDNA3 transfected cells (Figure 2A). However, expression of Rta in 293T cells stimulated hIL-6 expression, and resulted in progressively higher amounts of hIL-6 protein accumulating in the supernatant at 48 and 72 hr post-transfection (54.0 and 84.5 pg/ml, respectively).
To further establish the ability of Rta to activate the hIL-6 promoter and induce hIL-6 protein expression, we performed similar experiments in R1T cells. R1T cells manifest a significant level of basal hIL-6 expression\(^\text{19}\) and thus complement the use of 293T cells. The reporter plasmid phIL6-1200/SEAP was activated 27-fold by Rta in transient transfection reporter assays in R1T cells (Figure 1A). The fold activation in R1T cells is lower than that in 293T cells, due to the higher basal level of the reporter plasmid. Moreover, transfection of pcDNA3/Rta stimulated the expression of endogenous hIL-6 in R1T cells, when compared to transfection of pcDNA3, and resulted in hIL-6 levels of 1209, 5762, and 21447 pg/ml at 24, 48 and 72 hr post-transfection, respectively (Figure 2B).

Up-regulation of the hIL-6 gene has emerged as a common theme among herpesvirus infections, and multiple mechanisms may be involved.\(^\text{20-22}\) In the case of HHV-8/KSHV, latently-infected B cell lines (e.g. BC-1 and KS-1) express hIL-6 at high levels.\(^\text{3,4}\) This is due in part to the responsiveness of the hIL-6 promoter to an HHV-8/KSHV latent gene product, the latency-associated nuclear antigen.\(^\text{19}\) Because HHV-8/KSHV exists predominantly in a latent state in KS and PEL lesions, induction of hIL-6 expression by the latency-associated nuclear antigen may play a critical role in development of these malignancies. Here we have demonstrated that HHV-8/KSHV also stimulates hIL-6 expression through its lytic transcriptional activator Rta. We hypothesize that activation of hIL-6 by Rta plays an important role in lytic infections. This is especially relevant in the settings of HHV-8/KSHV-associated MCD. Our results are consistent with the high plasma hIL-6 levels observed in MCD patients and the fact that majority of the HHV-8/KSHV infected cells in MCD lesions express the viral lytic gene expression program driven by Rta.\(^\text{16,17}\)

Interestingly, in a separate study, we have demonstrated that Rta also strongly activates the HHV-8/KSHV-encoded vIL-6 gene.\(^\text{23}\) Like hIL-6, vIL-6 promotes the growth of IL-6 dependent B cells and activates signal transduction pathways. However, vIL-6 may stimulate a broader spectrum of target cells, because it requires only the ubiquitously expressed gp130 receptor, whereas hIL-6 requires both gp130 and IL-6R\(\alpha\) for signal transduction.\(^\text{14,15,24}\) On the other hand, the amount of vIL-6 required to stimulate the growth of IL-6 dependent B cells was greater than that of hIL-6, and the binding affinity of vIL-6 for soluble gp130 was determined to be 1000-fold lower than that of hIL-6/soluble IL-6R complex for gp130.\(^\text{25}\) Therefore, both hIL-6 and vIL-6 may be important in HHV-8/KSHV replication and pathogenesis, but they may play overlapping yet different roles.

Acknowledgments

We thank Mike Johnson and Jiabin An for excellent technical assistance, Dr. Tonia Symensma for critical reading of the manuscript, and members of the Sun and Martinez-Maza laboratories for discussion.

References


Figure 1. HHV-8/KSHV Rta activates the hIL-6 promoter in a reporter system. (A) Activation of the hIL-6 promoter by Rta in two different cell lines. Reporter plasmid pIL6-1200/SEAP (20 ng), pRL-CMV (2 ng), filler DNA (720 ng; plasmid DNA that lacks a mammalian promoter/enhancer), and either pcDNA3/Rta or pcDNA3 (50 ng), were transfected into 293T or R1T cells. Supernatants and cells were harvested at 48 hr post-transfection, and assayed for SEAP and Renilla luciferase activities, respectively. SEAP activities from the hIL6 promoter were normalized to the corresponding Renilla luciferase activities. Fold activation by Rta was calculated by comparing the normalized SEAP activity stimulated by Rta to that by pcDNA3. (B) Dose-dependent activation of the hIL-6 promoter by Rta in 293T cells. Cells were transfected with 20 ng of pIL6-1200/SEAP, 2 ng of pRL-CMV, 720 ng of filler DNA, as well as an increasing amount of pcDNA3/Rta (from 0 to 50 ng) and a correspondingly decreasing amount of pcDNA3 (from 50 to 0 ng) so that the total amount of pcDNA3 vector backbone remained the same. Reporter activities were assayed at 48 hr post-transfection; fold activation by different amounts of pcDNA3/Rta was calculated by comparing the normalized SEAP activities to that stimulated by 0 ng of pcDNA3/Rta and 50 ng of pcDNA3.
Figure 2. **HHV-8/KSHV Rta activates the endogenous hIL-6 gene.** pcDNA3/Rta or pcDNA3 (1 µg) was transfected into 293T (A) or R1T (B) cells. Supernatants were harvested 24, 48 and 72 hr later, diluted where appropriate and assayed for hIL-6 protein levels by ELISA. The average hIL-6 protein concentrations in the supernatants are indicated by horizontal bars, with the numbers (pg/ml) shown. The detection range of the ELISA kit is 7.8-500 pg/ml. The dotted line in (A) indicates the lowest detection limit of the kit. When the hIL-6 level in one or more experiments was lower than 7.8 pg/ml, the average for that time point is not calculated. A logarithmic scale is used in (B).
Rta of human herpesvirus 8/Kaposi's sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression

Hongyu Deng, Julia T Chu, Matthew B Rettig, Otoniel Martinez-Maza and Ren Sun